Coronavirus (COVID-19) - Latest Information for Patients and Visitors

(La más reciente información para pacientes y visitantes)

 

Read Now (Lea ahora)
800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

Media Outlet Highlights Novel Treatment Strategy for Pulmonary Embolism That Shows Exceptional Promise in Early Clinical Trials

View All News

Researchers at the Lewis Katz School of Medicine at Temple University have developed a device known as the Bashir Endovascular Catheter, which effectively dissolves pulmonary emboli in the lungs, with no major bleeding risk. The evidence comes from the prespecified interim analysis of the National Institutes of Health (NIH)-sponsored RESCUE trial, and interim data were presented October 5th at the VIVA (Vascular InterVentional Advances) 2021 Conference. Riyaz Bashir, MD, FACC, Professor of Medicine, Director of Vascular and Endovascular Medicine in the Department of Medicine, Section of Cardiology at the Katz School of Medicine and Temple University Hospital, is the co-inventor of the catheter. Parth Rali, MD, Associate Professor of Thoracic Medicine and Surgery at the Katz School of Medicine and Director of the Temple Pulmonary Embolism Response Team (PERT) Program, is the Site Principal Investigator of the trial. Vladimir Lakhter, DO, Assistant Professor of Medicine at the Katz School of Medicine, is an interventional cardiologist involved in the RESCUE trial. Daniel Edmundowicz, MS, MD, FACC, Chief of Cardiology at Temple University Hospital, Florence B. Bernheimer Distinguished Service Professorship Chair of Cardiology and Professor and Vice Chair of Program Development in the Department of Medicine at the Katz School of Medicine, and Medical Director of the Temple Heart and Vascular Institute, also provided perspective. Medical Xpress highlighted the news.